OrbiMed Advisors
Latest statistics and disclosures from Orbimed Advisors's latest quarterly 13F-HR filing:
- Top 5 stock holdings are EWTX, ELVN, LLY, MBX, Sinovac Biotech, and represent 30.71% of Orbimed Advisors's stock portfolio.
- Added to shares of these 10 stocks: UNH (+$71M), ASND (+$65M), HUM (+$65M), Odyssey Therapeutics (+$56M), ARQT (+$54M), COGT (+$53M), XBI (+$48M), AZN (+$46M), GPCR (+$39M), ABVX (+$37M).
- Started 37 new stock positions in SLS, AMLX, WAT, Revolution Medicines, AURA, Travere Therapeutics, SYRE, MNPR, ACAD, ERAS.
- Reduced shares in these 10 stocks: RCEL (-$303M), MDXH (-$286M), , ELVN (-$60M), PFE (-$55M), IRON (-$52M), DHR (-$50M), SION (-$43M), Ascendis Pharma A S (-$42M), ARGX (-$41M).
- Sold out of its positions in JBIO, ALHC, AMGN, Ascendis Pharma A S, AVTX, RCEL, BTSG, CCCC, CARL, CMPS. CGEM, DHR, ESPR, GILD, HRTX, Kalvista Pharmaceuticals, MYGN, PFE, REGN, Soleno Therapeutics, VTGN, MDXH, ADCT, QGEN.
- Orbimed Advisors was a net seller of stock by $-457M.
- Orbimed Advisors has $5.4B in assets under management (AUM), dropping by 4.57%.
- Central Index Key (CIK): 0001055951
Tip: Access up to 7 years of quarterly data
Positions held by OrbiMed Advisors consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Orbimed Advisors
Orbimed Advisors holds 123 positions in its portfolio as reported in the June 2026 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Edgewise Therapeutics (EWTX) | 11.7 | $631M | 16M | 40.63 |
|
|
| Enliven Therapeutics (ELVN) | 6.4 | $344M | -14% | 6.8M | 50.75 |
|
| Eli Lilly & Co. (LLY) | 5.7 | $309M | +8% | 258k | 1199.43 |
|
| Mbx Biosciences (MBX) | 3.5 | $189M | -5% | 3.4M | 55.20 |
|
| Sinovac Biotech SHS | 3.4 | $185M | 2.7M | 67.85 |
|
|
| Astrazeneca Ord (AZN) | 3.2 | $171M | +36% | 916k | 186.83 |
|
| Structure Therapeutics Sponsored Ads (GPCR) | 2.2 | $119M | +49% | 2.2M | 53.67 |
|
| Sionna Therapeutics (SION) | 2.1 | $112M | -27% | 2.6M | 43.99 |
|
| Corvus Pharmaceuticals (CRVS) | 2.0 | $107M | 7.2M | 14.94 |
|
|
| Arrivent Biopharma (AVBP) | 1.9 | $105M | 3.0M | 34.74 |
|
|
| Abivax Sa Sponsored Ads Call Option (ABVX) | 1.8 | $100M | +60% | 747k | 133.26 |
|
| Guardant Health (GH) | 1.6 | $88M | +34% | 584k | 150.03 |
|
| Argenx Se Sponsored Adr (ARGX) | 1.6 | $86M | -32% | 93k | 927.77 |
|
| Merck & Co (MRK) | 1.6 | $85M | 663k | 128.50 |
|
|
| Uniqure Nv SHS (QURE) | 1.5 | $83M | -15% | 1.8M | 46.06 |
|
| Praxis Precision Medicines I Com New (PRAX) | 1.4 | $77M | +33% | 230k | 334.79 |
|
| Edwards Lifesciences (EW) | 1.4 | $76M | -32% | 835k | 90.46 |
|
| Prelude Therapeutics (PRLD) | 1.4 | $73M | +25% | 14M | 5.33 |
|
| Dyne Therapeutics (DYN) | 1.3 | $72M | +10% | 3.2M | 22.21 |
|
| Natera (NTRA) | 1.3 | $71M | 262k | 271.45 |
|
|
| UnitedHealth (UNH) | 1.3 | $71M | NEW | 171k | 415.63 |
|
| Cg Oncology (CGON) | 1.3 | $69M | +2% | 973k | 71.05 |
|
| Silverback Therapeutics (SPRY) | 1.2 | $66M | 8.3M | 8.01 |
|
|
| Ascendis Pharma A/s Ord Shs (ASND) | 1.2 | $65M | NEW | 245k | 266.72 |
|
| Humana (HUM) | 1.2 | $65M | NEW | 164k | 397.22 |
|
| Cogent Biosciences (COGT) | 1.2 | $65M | +421% | 1.7M | 38.70 |
|
| Boston Scientific Corporation (BSX) | 1.2 | $63M | -37% | 1.5M | 42.68 |
|
| Intuitive Surgical Com New (ISRG) | 1.2 | $63M | -24% | 158k | 397.68 |
|
| Mineralys Therapeutics (MLYS) | 1.1 | $57M | +2% | 2.1M | 26.98 |
|
| Odyssey Therapeutics Common Stock | 1.0 | $56M | NEW | 3.0M | 18.71 |
|
| Xenon Pharmaceuticals (XENE) | 1.0 | $54M | -15% | 893k | 60.36 |
|
| Arcutis Biotherapeutics (ARQT) | 1.0 | $54M | NEW | 2.0M | 26.22 |
|
| Bristol Myers Squibb (BMY) | 1.0 | $53M | 925k | 57.62 |
|
|
| Q32 Bio (QTTB) | 1.0 | $53M | +83% | 4.1M | 12.74 |
|
| Palvella Therapeutics Inc Ne Call Option (PVLA) | 0.9 | $51M | +80% | 332k | 152.82 |
|
| Stryker Corporation (SYK) | 0.9 | $50M | -12% | 159k | 314.84 |
|
| Caris Life Sciences (CAI) | 0.9 | $50M | 2.8M | 17.82 |
|
|
| Anthem Call Option (ELV) | 0.9 | $48M | +8% | 125k | 386.73 |
|
| Spdr Series Trust St Str Sp Biot Put Option (XBI) | 0.9 | $48M | NEW | 300k | 158.25 |
|
| Thermo Fisher Scientific (TMO) | 0.8 | $46M | +95% | 91k | 501.36 |
|
| Shattuck Labs (STTK) | 0.8 | $44M | 6.3M | 6.94 |
|
|
| Upstream Bio (UPB) | 0.7 | $39M | 5.7M | 6.92 |
|
|
| Crinetics Pharmaceuticals In (CRNX) | 0.7 | $37M | 999k | 37.42 |
|
|
| Rhythm Pharmaceuticals (RYTM) | 0.7 | $36M | +2% | 323k | 111.03 |
|
| Syndax Pharmaceuticals (SNDX) | 0.6 | $34M | +60% | 1.5M | 21.86 |
|
| Forte Biosciences Com New (FBRX) | 0.6 | $34M | +31% | 1.6M | 21.25 |
|
| Compass Therapeutics (CMPX) | 0.6 | $33M | 15M | 2.19 |
|
|
| Nektar Therapeutics Com New (NKTR) | 0.6 | $33M | +69% | 465k | 69.81 |
|
| Krystal Biotech (KRYS) | 0.6 | $31M | +20% | 83k | 371.67 |
|
| Prelude Therapeutics Non Voting | 0.6 | $30M | -8% | 5.7M | 5.33 |
|
| Axsome Therapeutics (AXSM) | 0.5 | $29M | -45% | 118k | 244.77 |
|
| Kiniksa Pharmaceuticals Intl Ord Shs Cl A (KNSA) | 0.5 | $27M | +132% | 421k | 63.95 |
|
| Trevi Therapeutics (TRVI) | 0.5 | $27M | -41% | 1.4M | 18.65 |
|
| Disc Medicine (IRON) | 0.5 | $26M | -66% | 358k | 73.14 |
|
| West Pharmaceutical Services (WST) | 0.5 | $25M | NEW | 71k | 359.00 |
|
| Relmada Therapeutics (RLMD) | 0.5 | $25M | -23% | 3.6M | 6.92 |
|
| Urogen Pharma (URGN) | 0.5 | $25M | -22% | 676k | 36.80 |
|
| Sutro Biopharma Com Shs (STRO) | 0.5 | $25M | -7% | 744k | 33.20 |
|
| Savara (SVRA) | 0.5 | $24M | +523% | 4.0M | 6.16 |
|
| Neuropace (NPCE) | 0.4 | $24M | -28% | 1.5M | 15.89 |
|
| Aura Biosciences (AURA) | 0.4 | $24M | NEW | 3.3M | 7.10 |
|
| Protagonist Therapeutics (PTGX) | 0.4 | $24M | +356% | 192k | 122.58 |
|
| Revolution Medicines Call Option (RVMD) | 0.4 | $23M | +131% | 121k | 187.28 |
|
| Oric Pharmaceuticals (ORIC) | 0.4 | $22M | -25% | 2.0M | 10.83 |
|
| Cybin Com New (HELP) | 0.4 | $22M | -14% | 3.3M | 6.61 |
|
| BioCryst Pharmaceuticals (BCRX) | 0.3 | $19M | +29% | 1.9M | 10.00 |
|
| Bioage Labs (BIOA) | 0.3 | $18M | +5% | 752k | 24.51 |
|
| Lexeo Therapeutics (LXEO) | 0.3 | $18M | +9% | 3.9M | 4.66 |
|
| Aadi Bioscience (WHWK) | 0.3 | $18M | -5% | 3.9M | 4.58 |
|
| Definium Therapeutics Com Shs (DFTX) | 0.3 | $17M | -54% | 365k | 47.04 |
|
| Spyre Therapeutics Com New (SYRE) | 0.3 | $17M | NEW | 186k | 88.78 |
|
| Corbus Pharmaceuticals Hldgs Com New (CRBP) | 0.3 | $16M | 1.7M | 9.38 |
|
|
| Vera Therapeutics Cl A (VERA) | 0.3 | $16M | 370k | 42.91 |
|
|
| Alumis (ALMS) | 0.3 | $15M | 548k | 28.14 |
|
|
| Eyepoint Com New (EYPT) | 0.3 | $15M | 1.1M | 14.30 |
|
|
| Waters Corporation (WAT) | 0.3 | $15M | NEW | 40k | 375.04 |
|
| Monopar Therapeutics Com New (MNPR) | 0.3 | $15M | NEW | 157k | 92.59 |
|
| Travere Therapeutics (TVTX) | 0.3 | $14M | NEW | 253k | 56.81 |
|
| Taysha Gene Therapies Com Shs (TSHA) | 0.3 | $14M | NEW | 2.0M | 6.81 |
|
| Biogen Idec (BIIB) | 0.2 | $13M | 62k | 216.06 |
|
|
| Dianthus Therapeutics (DNTH) | 0.2 | $11M | NEW | 115k | 97.48 |
|
| Spruce Biosciences Com New (SPRB) | 0.2 | $11M | NEW | 200k | 54.00 |
|
| Lifestance Health Group (LFST) | 0.2 | $10M | +89% | 947k | 10.71 |
|
| Erasca (ERAS) | 0.2 | $9.1M | NEW | 496k | 18.32 |
|
| Protara Therapeutics Com Stk (TARA) | 0.2 | $8.5M | NEW | 2.2M | 3.82 |
|
| Keros Therapeutics (KROS) | 0.2 | $8.1M | 759k | 10.70 |
|
|
| Janux Therapeutics (JANX) | 0.1 | $8.1M | -46% | 525k | 15.36 |
|
| Tectonic Therapeutic (TECX) | 0.1 | $7.8M | 227k | 34.38 |
|
|
| Adicet Bio Com New (ACET) | 0.1 | $7.3M | -17% | 845k | 8.64 |
|
| Pharvaris N V (PHVS) | 0.1 | $7.1M | 205k | 34.58 |
|
|
| Alto Neuroscience Com Shs (ANRO) | 0.1 | $6.8M | +53% | 258k | 26.39 |
|
| Zentalis Pharmaceuticals (ZNTL) | 0.1 | $6.7M | NEW | 1.4M | 4.85 |
|
| Bright Minds Biosciences Com New (DRUG) | 0.1 | $6.5M | +132% | 93k | 70.20 |
|
| Alx Oncology Hldgs (ALXO) | 0.1 | $5.9M | 2.9M | 2.07 |
|
|
| Travere Therapeutics Note 0.500% 5/1 (Principal) | 0.1 | $5.9M | NEW | 5.0M | 1.18 |
|
| Xilio Therapeutics (XLO) | 0.1 | $5.7M | NEW | 592k | 9.58 |
|
| Bicara Therapeutics (BCAX) | 0.1 | $5.7M | -71% | 191k | 29.69 |
|
| Imagenebio (IMA) | 0.1 | $5.4M | +140% | 909k | 5.90 |
|
| Alnylam Pharmaceuticals (ALNY) | 0.1 | $5.1M | -85% | 17k | 301.03 |
|
| Palisade Bio (PALI) | 0.1 | $4.9M | 2.3M | 2.09 |
|
|
| Revolution Medicines Note 0.500% 5/0 (Principal) | 0.1 | $4.4M | NEW | 3.5M | 1.25 |
|
| Ataibeckley Com Shs (ATAI) | 0.1 | $4.2M | +129% | 798k | 5.27 |
|
| Ptc Therapeutics I (PTCT) | 0.1 | $4.0M | 49k | 81.57 |
|
|
| CryoLife (AORT) | 0.1 | $3.9M | +15% | 175k | 22.47 |
|
| Neumora Therapeutics (NMRA) | 0.1 | $3.6M | NEW | 2.1M | 1.70 |
|
| ACADIA Pharmaceuticals (ACAD) | 0.1 | $3.5M | NEW | 137k | 25.30 |
|
| Amylyx Pharmaceuticals (AMLX) | 0.1 | $3.3M | NEW | 183k | 17.96 |
|
| Tyra Biosciences (TYRA) | 0.1 | $3.3M | NEW | 102k | 31.94 |
|
| Rapport Therapeutics (RAPP) | 0.1 | $3.2M | NEW | 77k | 41.67 |
|
| Agomab Therapeutics Nv Sponsored Ads (AGMB) | 0.0 | $2.5M | NEW | 193k | 12.98 |
|
| Tarsus Pharmaceuticals (TARS) | 0.0 | $2.2M | NEW | 36k | 62.94 |
|
| Aclaris Therapeutics (ACRS) | 0.0 | $2.2M | NEW | 422k | 5.29 |
|
| Cytokinetics Com New (CYTK) | 0.0 | $2.2M | NEW | 26k | 85.19 |
|
| Inspiremd (NSPR) | 0.0 | $2.2M | 3.1M | 0.70 |
|
|
| Ocular Therapeutix (OCUL) | 0.0 | $2.2M | NEW | 220k | 9.82 |
|
| Evommune Com Shs (EVMN) | 0.0 | $2.1M | NEW | 161k | 13.29 |
|
| Belite Bio Sponsored Ads (BLTE) | 0.0 | $2.0M | NEW | 13k | 153.99 |
|
| Ovid Therapeutics (OVID) | 0.0 | $2.0M | NEW | 747k | 2.69 |
|
| Eupraxia Pharmaceuticals (EPRX) | 0.0 | $1.8M | NEW | 269k | 6.61 |
|
| Sellas Life Sciences Group I Com New Put Option (SLS) | 0.0 | $1.4M | NEW | 93k | 14.76 |
|
| Cogent Biosciences Note 1.625%11/1 (Principal) | 0.0 | $1.2M | 1.0M | 1.23 |
|
|
| Viridian Therapeutics Note 1.750% 5/1 (Principal) | 0.0 | $1.1M | NEW | 1.0M | 1.07 |
|
| Traws Pharma Com New (TRAW) | 0.0 | $1.0M | +98% | 1.2M | 0.84 |
|
Past Filings by Orbimed Advisors
SEC 13F filings are viewable for Orbimed Advisors going back to 2010
- Orbimed Advisors 2026 Q2 filed Aug. 14, 2026
- Orbimed Advisors 2026 Q1 filed May 15, 2026
- Orbimed Advisors 2025 Q4 filed Feb. 17, 2026
- Orbimed Advisors 2025 Q3 filed Nov. 14, 2025
- Orbimed Advisors 2025 Q2 filed Aug. 14, 2025
- Orbimed Advisors 2025 Q1 filed May 15, 2025
- Orbimed Advisors 2024 Q4 filed Feb. 14, 2025
- Orbimed Advisors 2024 Q3 filed Nov. 14, 2024
- Orbimed Advisors 2024 Q2 filed Aug. 14, 2024
- Orbimed Advisors 2024 Q1 filed May 15, 2024
- Orbimed Advisors 2023 Q4 filed Feb. 14, 2024
- Orbimed Advisors 2023 Q3 filed Nov. 14, 2023
- Orbimed Advisors 2023 Q2 filed Aug. 14, 2023
- Orbimed Advisors 2023 Q1 filed May 15, 2023
- Orbimed Advisors 2022 Q4 filed Feb. 14, 2023
- Orbimed Advisors 2022 Q3 filed Nov. 14, 2022